182 related articles for article (PubMed ID: 37587253)
1. Preliminary Study of Whole-Genome Bisulfite Sequencing and Transcriptome Sequencing in VHL Disease-Associated ccRCC.
Li L; Bao H; Xu Y; Yang W; Zhang Z; Ma K; Zhang K; Zhou J; Gong Y; Ci W; Gong K
Mol Diagn Ther; 2023 Nov; 27(6):741-752. PubMed ID: 37587253
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
3. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.
Beroukhim R; Brunet JP; Di Napoli A; Mertz KD; Seeley A; Pires MM; Linhart D; Worrell RA; Moch H; Rubin MA; Sellers WR; Meyerson M; Linehan WM; Kaelin WG; Signoretti S
Cancer Res; 2009 Jun; 69(11):4674-81. PubMed ID: 19470766
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
5. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
[TBL] [Abstract][Full Text] [Related]
6. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
7. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
[TBL] [Abstract][Full Text] [Related]
9. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
10. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.
Wang SS; Gu YF; Wolff N; Stefanius K; Christie A; Dey A; Hammer RE; Xie XJ; Rakheja D; Pedrosa I; Carroll T; McKay RM; Kapur P; Brugarolas J
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16538-43. PubMed ID: 25359211
[TBL] [Abstract][Full Text] [Related]
11. Natural history of Von Hippel-Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study.
Wang J; Zhang L; Qiu J; Li Z; Wu Y; Zhang C; Yao L; Gong K; Li X; Zhou L
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2631-2641. PubMed ID: 34709473
[TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
13. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract][Full Text] [Related]
14. VHL, the story of a tumour suppressor gene.
Gossage L; Eisen T; Maher ER
Nat Rev Cancer; 2015 Jan; 15(1):55-64. PubMed ID: 25533676
[TBL] [Abstract][Full Text] [Related]
15. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
[TBL] [Abstract][Full Text] [Related]
16. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
[TBL] [Abstract][Full Text] [Related]
17. VHL gene alterations in Italian patients with isolated renal cell carcinomas.
Muscarella LA; D'Agruma L; la Torre A; Gigante M; Coco M; Parrella P; Battaglia M; Carrieri G; Carella M; Zelante L; Fazio VM; Gesualdo L; Ranieri E
Int J Biol Markers; 2013 Jun; 28(2):208-15. PubMed ID: 23558940
[TBL] [Abstract][Full Text] [Related]
18. [Identification of the feature of immune cells infiltration in inherited renal carcinoma with von Hippel-Lindau syndrome].
Yang WP; Zhou JC; Zhang KN; Xu YW; Cai L; Gong YQ; Gong K
Zhonghua Yi Xue Za Zhi; 2021 Dec; 101(46):3789-3793. PubMed ID: 34895418
[No Abstract] [Full Text] [Related]
19. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
